Soliris
Soliris works by selectively inhibiting activation of specific proteins in the complement system (C5a and C5b), which play a role in the pathophysiology of multiple rare diseases.
Sage is now an In-Network provider with Humana (effective November 2023)
Our Insurances
Financial transparency is of the utmost importance to us. Use our calculator below to select your infusion treatment, and we’ll show you the initial cost of the treatment, the amount of financial assistance you can receive, typical out-of-pocket costs, and more.
Below, see the cost of the treatment, the amount of financial assistance available, and the typical out-of-pocket costs for those with Medicare or Commercial Insurance.
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Sage's Typical Out-Of-Pocket Cost per Visit
Enter your email below so that one of our specialists can connect with you with more information about treatment costs, scheduling an appointment, and more!
A Care Team member will be in touch with you shortly. If you're ready to schedule an appointment with us, click "Book an Appointment" below to get started. To read more about how we offer the lowest treatment costs to our clients, see Our Financial Promise.
Soliris works by selectively inhibiting activation of specific proteins in the complement system (C5a and C5b), which play a role in the pathophysiology of multiple rare diseases.
Vyvgart (efgartigimod alfa-fcab) is a prescription medication used for the treatment of generalized myasthenia gravis in adults who are positive for antibodies directed toward a protein called the acetylcholine receptor (anti-AChR antibody positive).
Ultomiris is a medication used for the treatment of generalized myasthenia gravis
(gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive as
well as those with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic
uremic syndrome (aHUS).